-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Protagenic Therapeutics, Inc.\new quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q3 2013 to Q2 2024.
- Protagenic Therapeutics, Inc.\new Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2024 was -$1.61M, a 32.8% decline year-over-year.
- Protagenic Therapeutics, Inc.\new Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending June 30, 2024 was -$6.4M, a 85.4% decline year-over-year.
- Protagenic Therapeutics, Inc.\new annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$5M, a 40.6% decline from 2022.
- Protagenic Therapeutics, Inc.\new annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$3.56M, a 21.4% increase from 2021.
- Protagenic Therapeutics, Inc.\new annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$4.52M, a 77.5% decline from 2020.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)